Last reviewed · How we verify
NCT07306598
[18F]NIDF PET Imaging in Tau-related Diseases
trial in Neurodegenerative Disease in 20 participants. Currently enrolling.
1 December 2030
Quick facts
| Lead sponsor | Tianjin Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 November 2025 |
| Primary completion | 1 December 2030 |
| Estimated completion | 1 December 2030 |
| Sites | 2 locations across China |
Conditions studied
- Neurodegenerative Disease — all drugs for Neurodegenerative Disease →
- Alzheimer s Disease — all drugs for Alzheimer s Disease →
- Tauopathies — all drugs for Tauopathies →
Sponsor
Tianjin Medical University
Who can join
Adults 18 to 90, any sex, with Neurodegenerative Disease or Alzheimer s Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07306598
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodegenerative Disease
Currently open trials in the same condition.
- NCT07361887 — Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. · NA · recruiting
- NCT07285954 — Mindfulness Walking Intervention to Enhance Resilience (iWalk) · NA · recruiting
- NCT06821230 — Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers · NA · recruiting
- NCT06755164 — Effects of Combined Aerobic and Cognitive Training in a Simultaneous or Sequential Paradigm on Cognition and Brain Funct · NA · active not recruiting
- NCT00271622 — The Neurodevelopmental and Behavioral Phenotyping Screening Protocol · recruiting
Other Tianjin Medical University trials
Trials by the same sponsor.
- NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
- NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting
- NCT06491979 — Vitamin and Unsaturated Fatty Acid Supplements in Healthy and Uveitis Human Subjects · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07306598 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
- Last refreshed: 29 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07306598.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing